Response from CEO, CHAI about the Quick Start program in November 2016

Response from CEO, CHAI about the Quick Start program in November 2016

Please click here

/ News

Share the Post

Related Posts

Letter from Community in Asia and Eastern Europe to Global Fund Board for Financing Hep C Treatment
BMS’ patent bid for Hep C treatment Daclatasvir Challenged
Know the interactions between HIV and Hep C medicines
A two pager of what you need to know of Sofosbuvir
Strategies to Secure Access to Generic HCV Medicines
20 YEARS AFTER THE TRIPS AGREEMENT, U.S. GOVERNMENT SCORES MASSIVE VICTORY FOR BIG PHARMA IN TPP DEAL
Patent Situation of The Key Product for Treatment of Hepatitis C: DACLASTAVIR – WHO working paper, revised version, Oct 2014
IAC a community group in Indonesia demanding national food and drugs authority to expedite registration process of DAA medicines in Indonesia